# Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)

> **NCT04330625** · PHASE1 · TERMINATED · sponsor: **Duke University** · enrollment: 1 (actual)

## Conditions studied

- Hyperglycemia Drug Induced

## Interventions

- **BIOLOGICAL:** REMD-477

## Key facts

- **NCT ID:** NCT04330625
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-13
- **Primary completion:** 2021-05-05
- **Final completion:** 2021-05-05
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Lack of enrollment
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04330625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04330625, "Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04330625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*